Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Advanced NSCLC with Pre-existing Autoimmune Disease
NCT03656627Phase 1Terminated
- Sponsor
- Alliance Foundation Trials
- Start
- Jun 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Alliance Foundation Trials. Primary endpoint: Dose-Limiting Toxicity at 48 Months. Started Jun 2019; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03656627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656627.